BENZOYL PEROXIDE AND CLINDAMYCIN PHOSPHATE
Clinical safety rating: safe
May enhance the effects of neuromuscular blocking agents Causes severe and sometimes fatal Clostridium difficile-associated diarrhea.
Benzoyl peroxide: oxidizes bacterial proteins via free radical release, reducing Cutibacterium acnes; keratolytic and comedolytic. Clindamycin phosphate: inhibits bacterial protein synthesis by binding to 50S ribosomal subunit, bacteriostatic against C. acnes.
| Metabolism | Benzoyl peroxide: metabolized to benzoic acid, then conjugated with glycine to hippuric acid, excreted renally. Clindamycin phosphate: hydrolyzed to clindamycin, primarily metabolized by CYP3A4 to N-demethyl clindamycin and sulfoxide metabolites, excreted in bile and urine. |
| Excretion | Benzoyl peroxide is metabolized to benzoic acid, which is excreted in urine as hippuric acid; clindamycin phosphate is hydrolyzed to clindamycin, which undergoes hepatic metabolism with about 10% excreted unchanged in urine, 3.6% in feces as active drug, and the remainder as metabolites. |
| Half-life | Clindamycin terminal elimination half-life is 2-4 hours in adults; benzoyl peroxide has minimal systemic absorption, so half-life is not clinically relevant. |
| Protein binding | Clindamycin: 60-94% bound to plasma proteins; benzoyl peroxide: not systemically absorbed, binding not applicable. |
| Volume of Distribution | Clindamycin Vd is 0.6-1.2 L/kg, indicating extensive tissue distribution; benzoyl peroxide: not applicable. |
| Bioavailability | Topical: Systemic absorption of clindamycin is minimal (approximately 4-5% of dose) from intact skin; benzoyl peroxide absorption is negligible (<2% of dose). |
| Onset of Action | Topical: Improvement in acne lesions may begin within 2 weeks; maximal effect often seen at 8-12 weeks. |
| Duration of Action | Topical: Once-daily application maintains clinical effect; continuous therapy is required to sustain acne suppression. |
Topical: Apply a thin film to affected areas twice daily (morning and evening). Each gram of gel contains 50 mg benzoyl peroxide and 10 mg clindamycin phosphate (as clindamycin).
| Dosage form | GEL |
| Renal impairment | No dosage adjustment required for topical use, as systemic absorption is minimal. |
| Liver impairment | No dosage adjustment required for topical use, as systemic absorption is minimal. |
| Pediatric use | Approved for children ≥12 years: same as adult dosing. For children <12 years, safety and efficacy not established. |
| Geriatric use | No specific dosage adjustment; use with caution due to potential for increased skin sensitivity and dryness. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
May enhance the effects of neuromuscular blocking agents Causes severe and sometimes fatal Clostridium difficile-associated diarrhea.
| FDA category | Human |
| Breastfeeding | Minimal systemic absorption of both components following topical application. Clindamycin is excreted in human milk but not quantified after topical use; M/P ratio not available. Benzoyl peroxide is not absorbed systemically after topical application. Caution with prolonged use on large areas. Consider discontinuing nursing or drug, weighing importance of drug to mother. |
| Teratogenic Risk |
■ FDA Black Box Warning
None
| Common Effects | Diarrhea (including C. difficile) |
| Serious Effects |
["Hypersensitivity to benzoyl peroxide, clindamycin, or any component","History of regional enteritis, ulcerative colitis, or antibiotic-associated colitis (relative due to clindamycin component)"]
| Precautions | ["Colitis: Clindamycin may cause Clostridioides difficile-associated diarrhea, even with topical use; discontinue if diarrhea occurs.","Hypersensitivity: Severe allergic reactions including anaphylaxis, angioedema, and urticaria reported.","Skin irritation: Benzoyl peroxide may cause excessive drying, erythema, and peeling; reduce frequency if irritation occurs.","Photosensitivity: Avoid excessive UV exposure; benzoyl peroxide may increase sun sensitivity."] |
| Food/Dietary |
Loading safety data…
| Topical benzoyl peroxide and clindamycin phosphate combination has minimal systemic absorption; no well-controlled studies in pregnant women. Clindamycin is not teratogenic in animal studies at topical doses. Benzoyl peroxide is not teratogenic in animal studies. Risk cannot be excluded. Use only if clearly needed, especially during first trimester. |
| Fetal Monitoring | No specific maternal or fetal monitoring required for topical use. If used on large areas of damaged skin or with occlusive dressings, monitor for signs of systemic clindamycin effects (e.g., gastrointestinal symptoms) due to potential increased absorption. |
| Fertility Effects | No known effects on fertility from topical benzoyl peroxide or clindamycin. Systemic clindamycin may rarely cause pseudomembranous colitis but not associated with fertility impairment. No data on ovulation or spermatogenesis. |
| No clinically significant food interactions; may be taken without regard to meals. |
| Clinical Pearls | Apply a pea-sized amount for full face; avoid contact with eyes, mouth, and mucous membranes. Concomitant use with other topical acne treatments may increase irritation. Do not use with soaps or cleansers containing sulfur, resorcinol, or salicylic acid. Monitor for signs of pseudomembranous colitis due to clindamycin; discontinue if diarrhea occurs. Can bleach hair and fabrics. |
| Patient Advice | Apply a thin layer to affected areas once or twice daily after washing. · Avoid contact with eyes, lips, and inside the nose. · May cause skin dryness, peeling, or redness; use moisturizer if needed. · Do not use on broken or sunburned skin. · Report persistent diarrhea to your healthcare provider immediately. · Wait at least 5 minutes after washing before applying. · Wash hands after application. · Keep away from bleach and avoid use on colored fabrics. |